Disease

Breast Cancer Metastatic

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 10, 2026 · OBSERVATIONAL STUDY

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

ClinicalTrials.gov

This is a registry record for an ongoing observational study with planned enrollment; no results are reported, making it a feasibility and imaging validation study in early phases.

PreliminaryNCT07586215 Breast Cancer Metastatic Fudan University

Reported

Planned enrollment86

Estimated total enrollment (regis…100

Primary outcome measurenegative predictive value (NPV)

SEP 4, 2026 · PHASE 1/2 TRIAL

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

ClinicalTrials.gov

This is a clinical trial registry record describing a planned Phase 1b/2 study with no results posted; it documents the study design and planned outcomes only.

PreliminaryHER2 Positive Metastatic Breast Cancer Patritumab deruxtecan Gustave Roussy, Cancer Campus, Grand Paris

Reported

Estimated enrollment152

Study phasePhase 1b/2

Primary outcome (Part 1): DLTs, s…21 months after enrollment start

AUG 19, 2026 · INTERVENTIONAL STUDY

Decision Support Tool for Patients With Advanced Breast Cancer

ClinicalTrials.gov

This is an active, uncontrolled pilot feasibility study evaluating acceptability and provider feasibility of a decision support tool in advanced breast cancer; no results are posted in this registry record.

PreliminaryDecision Support Tool Advanced Breast Cancer Stage 4 Breast Cancer

Reported

Estimated enrollment100

Primary outcome measure 1Patient-reported acceptability of COAST, 2–…

Primary outcome measure 2Patient-reported appropriateness of COAST,…